Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22320495 | 1.00 | GRM5 (0.34) | GRM5GRM1ESR2SMYD2CYP3A4 | |
| SCHEMBL22320496 | 1.00 | GRM5 (0.34) | GRM5GRM1ESR2SMYD2CYP3A4 | |
| SCHEMBL22320359 | 0.88 | SMYD2 (0.32) | GRM5GRM1SMYD2CYP3A4HTT | |
| SCHEMBL22320358 | 0.88 | SMYD2 (0.32) | GRM5GRM1SMYD2CYP3A4HTT | |
| SCHEMBL20972734 | 0.87 | GRM5 (0.35) | GRM5GRM1SMYD2CYP3A4HTT | |
| SCHEMBL22262251 | 0.87 | GRM5 (0.35) | GRM5GRM1SMYD2CYP3A4HTT | |
| SCHEMBL20972733 | 0.87 | GRM5 (0.35) | GRM5GRM1SMYD2CYP3A4HTT | |
| SCHEMBL20972636 | 0.86 | PDE10A (0.35) | GRM5GRM1SMYD2PDE10A | |
| SCHEMBL20972564 | 0.85 | GRM5 (0.34) | GRM5GRM1ESR2SMYD2CYP3A4 | |
| SCHEMBL20972562 | 0.85 | GRM5 (0.34) | GRM5GRM1ESR2SMYD2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | GRM5 4691/4885GRM1 4210/4885ESR2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.